Metastatik Meme Kanserinde Ardışık Antikor–İlaç Konjugatı Kullanımı: Tedavi Sıralaması ve Çapraz Direnç

Authors

Mehmet Ali Aslan
Esra Özer

Synopsis

Antibody–drug conjugates (ADCs) have expanded treatment options across distinct clinical subsets of metastatic breast cancer. As more patients become eligible for multiple ADCs, treatment selection after the first agent and cross-resistance within shared payload classes have become increasingly relevant. This narrative review examines clinical evidence for sequential ADC therapy alongside resistance involving target antigens, linkers, intracellular processing, and cytotoxic payloads. Randomized evidence supports trastuzumab deruxtecan after trastuzumab emtansine in HER2-positive disease. Retrospective series evaluating sequential trastuzumab deruxtecan and sacituzumab govitecan generally report shorter benefit with the second ADC, although disease control is observed in some patients. This observation alone does not establish molecular cross-resistance; later treatment lines, patient selection, and discontinuation due to toxicity affect interpretation. Antigen loss, impaired binding, defective intracellular processing, drug efflux, and TOP1 alterations represent distinct resistance mechanisms. Changing the antigen target may restore payload delivery in some experimental models without overcoming resistance to a shared cytotoxic target. The expansion of first-line ADC use requires reassessment of sequencing evidence derived from heavily pretreated populations. Clinical decisions should integrate duration of benefit, reasons for discontinuation, contemporary tumor characteristics, residual toxicity, central nervous system involvement, and available alternatives. Prospective clinical validation is needed to establish optimal sequences and biomarker-guided payload switching.

References

Verma S, Miles D, Gianni L, et al. Trastuzumab emtansine for HER2-positive advanced breast cancer. The New England Journal of Medicine. 2012;367(19): 1783-1791. doi:10.1056/NEJMoa1209124

Modi S, Jacot W, Yamashita T, et al. Trastuzumab deruxtecan in previously treated HER2-low advanced breast cancer. The New England Journal of Medicine. 2022;387(1): 9-20. doi:10.1056/NEJMoa2203690

Bardia A, Hurvitz SA, Tolaney SM, et al. Sacituzumab govitecan in metastatic triple-negative breast cancer. The New England Journal of Medicine. 2021;384(16): 1529-1541. doi:10.1056/NEJMoa2028485

Poumeaud F, Morisseau M, Cabel L, et al. Efficacy of administration sequence: sacituzumab govitecan and trastuzumab deruxtecan in HER2-low metastatic breast cancer. British Journal of Cancer. 2024;131(4): 702-708. doi:10.1038/s41416-024-02766-9

Huppert LA, Mahtani R, Fisch S, et al. Multicenter retrospective cohort study of the sequential use of the antibody-drug conjugates (ADCs) trastuzumab deruxtecan (T-DXd) and sacituzumab govitecan (SG) in patients with HER2-low metastatic breast cancer (MBC). npj Breast Cancer. 2025;11(1): 34. doi:10.1038/s41523-025-00748-5

Coates JT, Sun S, Leshchiner I, et al. Parallel genomic alterations of antigen and payload targets mediate polyclonal acquired clinical resistance to sacituzumab govitecan in triple-negative breast cancer. Cancer Discovery. 2021;11(10): 2436-2445. doi:10.1158/2159-8290.CD-21-0702

André F, Park YH, Kim SB, et al. Trastuzumab deruxtecan versus treatment of physician’s choice in patients with HER2-positive metastatic breast cancer (DESTINY-Breast02): a randomised, open-label, multicentre, phase 3 trial. The Lancet. 2023;401(10390): 1773-1785. doi:10.1016/S0140-6736(23)00725-0

Abelman RO, Wu B, Barnes H, et al. TOP1 mutations and cross-resistance to antibody-drug conjugates in patients with metastatic breast cancer. Clinical Cancer Research. 2025;31(10): 1966-1974. doi:10.1158/1078-0432.CCR-24-2771

Tolaney SM, Jiang Z, Zhang Q, et al. Trastuzumab deruxtecan plus pertuzumab for HER2-positive metastatic breast cancer. The New England Journal of Medicine. 2026;394(6): 551-562. doi:10.1056/NEJMoa2508668

Cortés J, Punie K, Barrios C, et al. Sacituzumab govitecan in untreated, advanced triple-negative breast cancer. The New England Journal of Medicine. 2025;393(19): 1912-1925. doi:10.1056/NEJMoa2511734

Tolaney SM, de Azambuja E, Kalinsky K, et al. Sacituzumab govitecan plus pembrolizumab for advanced triple-negative breast cancer. The New England Journal of Medicine. 2026;394(4): 354-366. doi:10.1056/NEJMoa2508959

Ogitani Y, Aida T, Hagihara K, et al. DS-8201a, a novel HER2-targeting ADC with a novel DNA topoisomerase I inhibitor, demonstrates a promising antitumor efficacy with differentiation from T-DM1. Clinical Cancer Research. 2016;22(20): 5097-5108. doi:10.1158/1078-0432.CCR-15-2822

Ogitani Y, Hagihara K, Oitate M, et al. Bystander killing effect of DS-8201a, a novel anti-human epidermal growth factor receptor 2 antibody-drug conjugate, in tumors with human epidermal growth factor receptor 2 heterogeneity. Cancer Science. 2016;107(7): 1039-1046. doi:10.1111/cas.12966

Hamblett KJ, Jacob AP, Gurgel JL, et al. SLC46A3 is required to transport catabolites of noncleavable antibody maytansine conjugates from the lysosome to the cytoplasm. Cancer Research. 2015;75(24): 5329-5340. doi:10.1158/0008-5472.CAN-15-1610

Ríos-Luci C, García-Alonso S, Díaz-Rodríguez E, et al. Resistance to the antibody-drug conjugate T-DM1 is based in a reduction in lysosomal proteolytic activity. Cancer Research. 2017;77(17): 4639-4651. doi:10.1158/0008-5472.CAN-16-3127

Okajima D, Yasuda S, Maejima T, et al. Datopotamab Deruxtecan, a Novel TROP2-directed Antibody–drug Conjugate, Demonstrates Potent Antitumor Activity by Efficient Drug Delivery to Tumor Cells. Mol Cancer Ther. 2021;20(12):2329–2340. doi:10.1158/1535-7163.MCT-21-0206

Bardia A, Jhaveri K, Im SA, et al. Datopotamab deruxtecan versus chemotherapy in previously treated inoperable/metastatic hormone receptor-positive human epidermal growth factor receptor 2-negative breast cancer: primary results from TROPION-Breast01. Journal of Clinical Oncology. 2025;43(3): 285-296. doi:10.1200/JCO.24.00920

Khera E, Cilliers C, Smith MD, et al. Quantifying ADC bystander payload penetration with cellular resolution using pharmacodynamic mapping. Neoplasia. 2021;23(2):210–221. doi:10.1016/j.neo.2020.12.001

Kumagai K, Aida T, Tsuchiya Y, Kishino Y, Kai K, Mori K. Interstitial pneumonitis related to trastuzumab deruxtecan, a human epidermal growth factor receptor 2-targeting Ab–drug conjugate, in monkeys. Cancer Sci. 2020;111(12):4636–4645. doi:10.1111/cas.14686

U.S. Food and Drug Administration. ENHERTU (fam-trastuzumab deruxtecan-nxki) prescribing information. Aralık 2025. https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/761139s038s042lbl.pdf

Modi S, Saura C, Yamashita T, et al. Trastuzumab deruxtecan in previously treated HER2-positive breast cancer. The New England Journal of Medicine. 2020;382(7): 610-621. doi:10.1056/NEJMoa1914510

Cortés J, Hurvitz SA, Im SA, et al. Trastuzumab deruxtecan versus trastuzumab emtansine in HER2-positive metastatic breast cancer: long-term survival analysis of the DESTINY-Breast03 trial. Nature Medicine. 2024;30(8): 2208-2215. doi:10.1038/s41591-024-03021-7

U.S. Food and Drug Administration. FDA approves fam-trastuzumab deruxtecan-nxki with pertuzumab for unresectable or metastatic HER2-positive breast cancer. 15 Aralık 2025. Erişim tarihi: 30 Eylül 2026. https://www.fda.gov/drugs/drug-approvals-and-databases/fda-approves-fam-trastuzumab-deruxtecan-nxki-pertuzumab-unresectable-or-metastatic-her2-positive

Rugo HS, Bardia A, Marmé F, et al. Sacituzumab govitecan in hormone receptor-positive/human epidermal growth factor receptor 2-negative metastatic breast cancer. Journal of Clinical Oncology. 2022;40(29): 3365-3376. doi:10.1200/JCO.22.01002

Rugo HS, Bardia A, Marmé F, et al. Overall survival with sacituzumab govitecan in hormone receptor-positive and human epidermal growth factor receptor 2-negative metastatic breast cancer (TROPiCS-02): a randomised, open-label, multicentre, phase 3 trial. The Lancet. 2023;402(10411): 1423-1433. doi:10.1016/S0140-6736(23)01245-X

Pistilli B, Jhaveri K, Im SA, et al. Datopotamab deruxtecan versus chemotherapy in previously treated inoperable/metastatic hormone receptor-positive, HER2-negative breast cancer: final overall survival analysis of the phase III TROPION-Breast01 study. Annals of Oncology. 2026;37(5): 663-674. doi:10.1016/j.annonc.2025.12.017

U.S. Food and Drug Administration. FDA approves datopotamab deruxtecan-dlnk for unresectable or metastatic triple-negative breast cancer. 22 Mayıs 2026. Erişim tarihi: 30 Eylül 2026. https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-datopotamab-deruxtecan-dlnk-unresectable-or-metastatic-triple-negative-breast-cancer

U.S. Food and Drug Administration. FDA approves sacituzumab govitecan-hziy as monotherapy and in combination with pembrolizumab for first-line treatment of triple-negative breast cancer. 24 Haziran 2026. Erişim tarihi: 30 Eylül 2026. https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-sacituzumab-govitecan-hziy-monotherapy-and-combination-pembrolizumab-first-line

Krop IE, Masuda N, Mukohara T, et al. Patritumab deruxtecan (HER3-DXd), a human epidermal growth factor receptor 3-directed antibody-drug conjugate, in patients with previously treated human epidermal growth factor receptor 3-expressing metastatic breast cancer: a multicenter, phase I/II trial. Journal of Clinical Oncology. 2023;41(36): 5550-5560. doi:10.1200/JCO.23.00882

Yin Y, Fan Y, Ouyang Q, et al. Sacituzumab tirumotecan in previously treated metastatic triple-negative breast cancer: a randomized phase 3 trial. Nature Medicine. 2025;31(6): 1969-1975. doi:10.1038/s41591-025-03630-w

Turner N, Saura C, Aftimos P, et al. Trastuzumab duocarmazine in pretreated human epidermal growth factor receptor 2-positive advanced or metastatic breast cancer: an open-label, randomized, phase III trial (TULIP). Journal of Clinical Oncology. 2025;43(5): 513-523. doi:10.1200/JCO.24.00529

Nadal-Serrano M, Morancho B, Escrivá-de-Romaní S, et al. The second generation antibody-drug conjugate SYD985 overcomes resistances to T-DM1. Cancers. 2020;12(3): 670. doi:10.3390/cancers12030670

Frenel JS, Zeghondy J, Guérin-Charbonnel C, et al. Tucatinib combination treatment after trastuzumab-deruxtecan in patients with ERBB2-positive metastatic breast cancer. JAMA Network Open. 2024;7(4): e244435. doi:10.1001/jamanetworkopen.2024.4435

Wolff AC, Somerfield MR, Dowsett M, et al. Human epidermal growth factor receptor 2 testing in breast cancer: ASCO–College of American Pathologists guideline update. Journal of Clinical Oncology. 2023;41(22): 3867-3872. doi:10.1200/JCO.22.02864

Bardia A, Hu X, Dent R, et al. Trastuzumab deruxtecan after endocrine therapy in metastatic breast cancer. The New England Journal of Medicine. 2024;391(22): 2110-2122. doi:10.1056/NEJMoa2407086

Modi S, Jacot W, Iwata H, et al. Trastuzumab deruxtecan in HER2-low metastatic breast cancer: long-term survival analysis of the randomized, phase 3 DESTINY-Breast04 trial. Nature Medicine. 2025;31(12): 4205-4213. doi:10.1038/s41591-025-03981-4

Mai N, Klar Lieberman MM, Ferraro E, et al. Sequential antibody-drug conjugate therapy in patients with metastatic breast cancer treated with sacituzumab govitecan and trastuzumab deruxtecan. JCO Precision Oncology. 2025;9: e2400898. doi:10.1200/PO-24-00898

Tarantino P, Lee D, Foldi J, et al. Outcomes of subsequent treatment regimens after trastuzumab deruxtecan in patients with metastatic breast cancer. J Natl Cancer Inst. 2025;117(11):2327–2335. doi:10.1093/jnci/djaf220

Cardoso F, Paluch-Shimon S, Schumacher-Wulf E, et al. 6th and 7th International consensus guidelines for the management of advanced breast cancer (ABC guidelines 6 and 7). The Breast. 2024;76:103756. doi:10.1016/j.breast.2024.103756

Dent R, Shao Z, Schmid P, et al. Datopotamab deruxtecan in patients with untreated, advanced triple-negative breast cancer (TROPION-Breast02): a randomised, open-label, international, phase III trial. Annals of Oncology. 2026;37(8): 1066-1080. doi:10.1016/j.annonc.2026.03.008

Chen W, Gupta A, Mai N, et al. Trastuzumab deruxtecan resistance via loss of HER2 expression and binding. Cancer Discovery. 2026;16(2): 235-249. doi:10.1158/2159-8290.CD-25-0647

Almstedt K, Krauthauser L, Kappenberg F, et al. Discordance of HER2-low between primary tumors and matched distant metastases in breast cancer. Cancers. 2023;15(5): 1413. doi:10.3390/cancers15051413

Mosele F, Deluche E, Lusque A, et al. Trastuzumab deruxtecan in metastatic breast cancer with variable HER2 expression: the phase 2 DAISY trial. Nature Medicine. 2023;29(8): 2110-2120. doi:10.1038/s41591-023-02478-2

Bardia A, Tolaney SM, Punie K, et al. Biomarker analyses in the phase III ASCENT study of sacituzumab govitecan versus chemotherapy in patients with metastatic triple-negative breast cancer. Annals of Oncology. 2021;32(9): 1148-1156. doi:10.1016/j.annonc.2021.06.002

Li G, Guo J, Shen BQ, et al. Mechanisms of acquired resistance to trastuzumab emtansine in breast cancer cells. Molecular Cancer Therapeutics. 2018;17(7): 1441-1453. doi:10.1158/1535-7163.MCT-17-0296

Rampa DR, Seo M, Ogata N, et al. Payload diversification overcomes resistance and guides sequential antibody-drug conjugate therapy in breast cancer. Clinical Cancer Research. 2026;32(8): 1454-1461. doi:10.1158/1078-0432.CCR-25-3321

Zoeller JJ, Vagodny A, Taneja K, et al. Neutralization of BCL-2/XL Enhances the Cytotoxicity of T-DM1 In Vivo. Molecular Cancer Therapeutics. 2019;18(6):1115–1126. doi:10.1158/1535-7163.MCT-18-0743

Pascual J, Attard G, Bidard FC, et al. ESMO recommendations on the use of circulating tumour DNA assays for patients with cancer: a report from the ESMO Precision Medicine Working Group. Annals of Oncology. 2022;33(8):750–768. doi:10.1016/j.annonc.2022.05.520

Harbeck N, Ciruelos E, Jerusalem G, et al. Trastuzumab deruxtecan in HER2-positive advanced breast cancer with or without brain metastases: a phase 3b/4 trial. Nature Medicine. 2024;30(12): 3717-3727. doi:10.1038/s41591-024-03261-7

Hu X, Curigliano G, Yonemori K, et al. Patient-reported outcomes with trastuzumab deruxtecan in hormone receptor-positive, HER2-low or HER2-ultralow metastatic breast cancer: results from the randomized DESTINY-Breast06 trial. ESMO Open. 2025;10(5): 105082. doi:10.1016/j.esmoop.2025.105082

Fehm T, Cottone F, Dunton K, et al. Trastuzumab deruxtecan versus treatment of physician’s choice in patients with HER2-positive metastatic breast cancer (DESTINY-Breast02): patient-reported outcomes from a randomised, open-label, multicentre, phase 3 trial. Lancet Oncology. 2024;25(5):614–625. doi:10.1016/S1470-2045(24)00128-1

Pistilli B, Mosele F, Corcos N, et al. Patritumab deruxtecan in HR+HER2− advanced breast cancer: a phase 2 trial. Nature Medicine. 2025;31(10): 3492-3503. doi:10.1038/s41591-025-03885-3

Yamazaki CM, Yamaguchi A, Anami Y, et al. Antibody-drug conjugates with dual payloads for combating breast tumor heterogeneity and drug resistance. Nature Communications. 2021;12:3528. doi:10.1038/s41467-021-23793-7

Lavori PW, Dawson R. Introduction to dynamic treatment strategies and sequential multiple assignment randomization. Clinical Trials. 2014;11(4):393–399. doi:10.1177/1740774514527651

Published

November 16, 2026

License

License